RIVENDELL GROUP LLP for GENENTECH
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Issues related to FDA & HHS program funding; FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Medicare/Medicaid MMM
Issues related to H.R. 6, the 21st Century CURES Act; Concerns regarding Medicare policies for Part B drugs; Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; Issues relating to Prescription Drug User Fee Act and ASP +6; Issues related to comparative effectiveness and follow-on biologics; Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); Issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax extenders; Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Copyright/Patent/Trademark CPT
Concerns regarding Medicare policies for Part B drugs; Issues related to the 340B Drug discount program
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Health Issues HCR
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); Issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Reform of 340B program; Cancer Patient Protection; Ongoing issues related to the implementation of the Affordable Care Act; Comparative effectiveness research, and FDA approval of follow-on biologics; Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit;
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW LAWRENCE BERZOK | LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch |
| NICK KOLOVOS | LA and Counsel, Rep. Anna Eshoo |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.